Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older [ID6542]

  • Awaiting development
  • GID-TA11525
  • Expected publication date: 

Suggested remit: To appraise the clinical and cost effectiveness of Setmelanotide within its marketing authorisation for treating acquired hypothalamic obesity